Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people's lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. The company's Helium Plasma Technology is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. Renuvion offers surgeons and physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.
Company profile
Ticker
APYX
Exchange
Website
CEO
Robert Gershon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AN CON GENETICS INC, BOVIE MEDICAL CORP, BOVIE MEDICAL Corp
SEC CIK
Corporate docs
Subsidiaries
Apyx China Holding Corp. • Apyx SY Medical Devices (NINGBO) Co., LTD. ...
IRS number
112644611
APYX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
11 May 23
8-K
Entry into a Material Definitive Agreement
18 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook
16 Mar 23
8-K
Entry into a Material Definitive Agreement
15 Mar 23
8-K
Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial
24 Feb 23
8-K
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results
10 Jan 23
EFFECT
Notice of effectiveness
5 Dec 22
Transcripts
APYX
Earnings call transcript
2023 Q1
11 May 23
APYX
Earnings call transcript
2022 Q4
16 Mar 23
APYX
Earnings call transcript
2022 Q3
10 Nov 22
APYX
Earnings call transcript
2022 Q2
14 Aug 22
APYX
Earnings call transcript
2022 Q1
12 May 22
APYX
Earnings call transcript
2021 Q4
17 Mar 22
APYX
Earnings call transcript
2021 Q3
12 Nov 21
APYX
Earnings call transcript
2021 Q2
12 Aug 21
APYX
Earnings call transcript
2021 Q1
12 May 21
APYX
Earnings call transcript
2020 Q4
31 Mar 21
Latest ownership filings
SC 13G
Divisadero Street Capital Management, LP
19 May 23
SC 13G
HIRSCHMAN ORIN
12 May 23
4
Craig A. Swandal
22 Mar 23
SC 13G/A
PURA VIDA INVESTMENTS, LLC
14 Feb 23
SC 13G/A
Archon Capital Management LLC
13 Feb 23
4
Todd Hornsby
13 Jan 23
4
MOSHE CITRONOWICZ
13 Jan 23
4
Tara Semb
13 Jan 23
4
Charles D. Goodwin II
13 Jan 23
SC 13G/A
Cowen Financial Products LLC
11 Jan 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 16.26 mm | 16.26 mm | 16.26 mm | 16.26 mm | 16.26 mm | 16.26 mm |
| Cash burn (monthly) | (no burn) | 831.58 k | 1.93 mm | 1.96 mm | 627.00 k | 1.47 mm |
| Cash used (since last report) | n/a | 1.87 mm | 4.34 mm | 4.40 mm | 1.41 mm | 3.30 mm |
| Cash remaining | n/a | 14.39 mm | 11.92 mm | 11.86 mm | 14.85 mm | 12.95 mm |
| Runway (months of cash) | n/a | 17.3 | 6.2 | 6.0 | 23.7 | 8.8 |
Institutional ownership, Q1 2023
62.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 54 |
| Opened positions | 10 |
| Closed positions | 8 |
| Increased positions | 12 |
| Reduced positions | 15 |
| 13F shares | Current |
|---|---|
| Total value | 53.50 bn |
| Total shares | 21.74 mm |
| Total puts | 1.00 k |
| Total calls | 6.60 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Archon Capital Management | 3.45 mm | $9.94 bn |
| RTW Investments | 3.40 mm | $9.79 bn |
| Cowen And | 1.78 mm | $5.11 bn |
| Cowen Financial Products | 1.78 mm | $4.16 mm |
| Vanguard | 1.49 mm | $4.28 bn |
| Pura Vida Investments | 1.47 mm | $4.24 bn |
| Royce & Associates | 1.46 mm | $4.20 bn |
| Taylor Frigon Capital Management | 804.43 k | $2.32 bn |
| Horizon Kinetics Asset Management | 615.00 k | $1.77 bn |
| Cowen Prime Advisors | 602.18 k | $2.05 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 11 Jan 23 | Goodwin Charles D. II | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.5 | 243,000 | 607.50 k | 243,000 |
| 11 Jan 23 | Tara Semb | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.5 | 96,000 | 240.00 k | 96,000 |
| 11 Jan 23 | Todd Hornsby | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.5 | 100,000 | 250.00 k | 100,000 |
| 11 Jan 23 | Moshe Citronowicz | Stock Option (Option to Buy) Common Stock | Grant | Acquire A | No | No | 2.5 | 72,000 | 180.00 k | 72,000 |
| 29 Aug 22 | Goodwin Charles D. II | Common Stock | Buy | Acquire P | No | No | 5.97 | 9,750 | 58.21 k | 40,000 |
| 29 Aug 22 | Goodwin Charles D. II | Common Stock | Buy | Acquire P | No | No | 5.93 | 2,000 | 11.86 k | 30,250 |
News
JMP Securities Reiterates Market Perform on Apyx Medical
24 May 23
JMP Securities Maintains Market Perform on Apyx Medicalto Market Perform
24 May 23
12 Health Care Stocks Moving In Friday's Intraday Session
12 May 23
Lake Street Maintains Buy on Apyx Medical, Raises Price Target to $6
12 May 23
Earnings Scheduled For May 11, 2023
11 May 23
Press releases
Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
11 May 23
RENUVION® RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTION
2 May 23
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring
28 Apr 23
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
5 Apr 23
Renuvion Wins ADDY® Award for #ThisIsMe Campaign
27 Mar 23